Ovarian cancer drug trial aims to unlock DNA secrets before surgery
NCT ID NCT02659241
First seen Nov 01, 2025 · Last updated Jun 21, 2026 · Updated 34 times
Summary
This early-phase trial is testing a drug called adavosertib in 38 people with advanced ovarian, fallopian tube, or peritoneal cancer. Participants take the drug for up to 28 days before their scheduled surgery. Researchers will compare tumor DNA before and after treatment to see how the drug affects cancer cells. The goal is not to cure the cancer now, but to learn how the drug works at the DNA level, which could help design better treatments in the future.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FALLOPIAN TUBE HIGH GRADE SEROUS ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
-
MD Anderson League City
League City, Texas, 77573, United States
-
MD Anderson West Houston
Houston, Texas, 77079, United States
-
MD Anderson in Sugar Land
Sugar Land, Texas, 77478, United States
-
MD Anderson in The Woodlands
Conroe, Texas, 77384, United States
-
Memorial Hermann Memorial City Medical Center
Houston, Texas, 77024, United States
-
OHSU Knight Cancer Institute
Portland, Oregon, 97239, United States
-
The Woman's Hospital of Texas
Houston, Texas, 77054, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
adavosertib (a drug that blocks a protein called Wee1)
What this could lead to
If successful, this study could help doctors understand how adavosertib changes tumor DNA, potentially leading to more effective treatment plans for ovarian cancer.
What could go wrong
This is a very early, small pilot study with only 38 participants. It is designed to measure DNA changes, not to prove the drug works as a treatment. The drug may not affect tumors as hoped.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.